Obesity and Leukemia: Biological Mechanisms, Perspectives, and Challenges
- PMID: 38159164
- PMCID: PMC10933194
- DOI: 10.1007/s13679-023-00542-z
Obesity and Leukemia: Biological Mechanisms, Perspectives, and Challenges
Abstract
Purpose of review: To examine the epidemiological data on obesity and leukemia; evaluate the effect of obesity on leukemia outcomes in childhood acute lymphoblastic leukemia (ALL) survivors; assess the potential mechanisms through which obesity may increase the risk of leukemia; and provide the effects of obesity management on leukemia. Preventive (diet, physical exercise, obesity pharmacotherapy, bariatric surgery) measures, repurposing drugs, candidate therapeutic agents targeting oncogenic pathways of obesity and insulin resistance in leukemia as well as challenges of the COVID-19 pandemic are also discussed.
Recent findings: Obesity has been implicated in the development of 13 cancers, such as breast, endometrial, colon, renal, esophageal cancers, and multiple myeloma. Leukemia is estimated to account for approximately 2.5% and 3.1% of all new cancer incidence and mortality, respectively, while it represents the most frequent cancer in children younger than 5 years. Current evidence indicates that obesity may have an impact on the risk of leukemia. Increased birthweight may be associated with the development of childhood leukemia. Obesity is also associated with worse outcomes and increased mortality in leukemic patients. However, there are several limitations and challenges in meta-analyses and epidemiological studies. In addition, weight gain may occur in a substantial number of childhood ALL survivors while the majority of studies have documented an increased risk of relapse and mortality among patients with childhood ALL and obesity. The main pathophysiological pathways linking obesity to leukemia include bone marrow adipose tissue; hormones such as insulin and the insulin-like growth factor system as well as sex hormones; pro-inflammatory cytokines, such as IL-6 and TNF-α; adipocytokines, such as adiponectin, leptin, resistin, and visfatin; dyslipidemia and lipid signaling; chronic low-grade inflammation and oxidative stress; and other emerging mechanisms. Obesity represents a risk factor for leukemia, being among the only known risk factors that could be prevented or modified through weight loss, healthy diet, and physical exercise. Pharmacological interventions, repurposing drugs used for cardiometabolic comorbidities, and bariatric surgery may be recommended for leukemia and obesity-related cancer prevention.
Keywords: Adipokine; Adiposity; Body mass index; Childhood leukemia; Epidemiology; Leukemia; Obesity.
© 2023. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10933194/bin/13679_2023_542_Fig1_HTML.gif)
Similar articles
-
Obesity and multiple myeloma: Emerging mechanisms and perspectives.Semin Cancer Biol. 2023 Jul;92:45-60. doi: 10.1016/j.semcancer.2023.04.003. Epub 2023 Apr 6. Semin Cancer Biol. 2023. PMID: 37030643 Review.
-
Biomarkers of cardiometabolic complications in survivors of childhood acute lymphoblastic leukemia.Sci Rep. 2020 Dec 9;10(1):21507. doi: 10.1038/s41598-020-78493-x. Sci Rep. 2020. PMID: 33299020 Free PMC article.
-
Adipokines, insulin resistance, and adiposity as a predictors of metabolic syndrome in child survivors of lymphoma and acute lymphoblastic leukemia of a developing country.BMC Cancer. 2017 Feb 13;17(1):125. doi: 10.1186/s12885-017-3097-8. BMC Cancer. 2017. PMID: 28193268 Free PMC article.
-
[Markers of metabolic syndrome and peptides regulating metabolism in survivors of childhood acute lymphoblastic leukemia].Przegl Lek. 2011;68(9):592-6. Przegl Lek. 2011. PMID: 22335007 Polish.
-
Obesity in patients with acute lymphoblastic leukemia in childhood.Ital J Pediatr. 2012 Jan 27;38:4. doi: 10.1186/1824-7288-38-4. Ital J Pediatr. 2012. PMID: 22284631 Free PMC article. Review.
References
-
- Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO classification of tumours of haematopoietic and lymphoid tissues. WHO Classification of Tumours, Revised 4th Edition, Volume 2. International Agency for Research on Cancer; 2017.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials